CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)

The purpose is to study the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CAR20(NAP)-T for patients with B-cell malignancies.

Trial Details

NCT ID
NCT06002659
Phase
PHASE1 / PHASE2
Sponsor
Uppsala University
Status
RECRUITING
Cancer Type
T-Cell Lymphoma Lymphoma
Interventions
  • CAR20(NAP)-T
  • Cyclophosphamide
  • Fludarabine
Locations (sample)
  • Stockholm, Sweden|59.32938,18.06871
  • Uppsala, Sweden|59.85882,17.63889

Key Eligibility Criteria

  • Signed informed consent.
  • Relapsed or refractory CD20+ large B-cell lymphoma (DLBCL, NOS or high-grade malignant B-cell lymphoma), mantle cell lymphoma or indolent lymphoma.
  • The patient should have been treated with at least one line of therapy and have no curative treatment option, assessed by the Investigator and docu…
  • Relapsed or refractory CD20+ B-cell lymphoma that are not suitable to receive clinically approved CD19-directed CAR T cell treatment

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find T-Cell Lymphoma Lymphoma Trials on Trialify →